Suven Pharmaceuticals Ltd. News and Updates

Name: Latest research reports of Suven Pharmaceuticals Ltd. authored by ICICI Securities Limited and published by - Trendlyne research reports.
Item: Suven Pharmaceuticals Ltd.
Rating: 5
Author: ICICI Securities Limited

Keep track of all breaking news on Suven Pharmaceuticals Ltd. from all sources in a single place.

Suven Pharmaceuticals Ltd.

29 Mar 2025

1151.00

3.68%

Suven Pharma Eyes $1-Billion Revenue By 2030, Driven By CDMO Expansion

NDTV Profit

Executive Chairman Vivek Sharma said that Suven Pharmaceuticals remains optimistic about its business trajectory, particularly in the high-growth CDMO sector.

Number of FII/FPI investors increased from 181 to 201 in Dec 2024 qtr.

NCLT approves amalgamation of Suven Pharma, Cohance Lifesciences

Business Standard | 28 Mar 2025 1 more

Suven Pharmaceuticals Ltd.

25 Mar 2025

1151.00

3.68%

Suven Pharma Gets 'Buy' On ICICI Securities Initiation, Sees 19% Upside

NDTV Profit

ICICI Securities initiates coverage on Suven Pharma with a Buy rating and a target price of Rs 1,400 (upside of ~19%).

Number of FII/FPI investors increased from 181 to 201 in Dec 2024 qtr.

Suven Pharmaceuticals Ltd.

25 Mar 2025

1151.00

3.68%

A distinct CDMO in the making

Buy: Suven Pharmaceuticals Ltd.

Recommendation Target

ICICI Securities Limited

Suven’s rapid ascendance in the CDMO space has been remarkable. It has journeyed from being a small molecule-focused CDMO to achieving eminence as one of the few CDMOs in India that offers contract manufacturing of oligonucleotides and ADCs.

Number of FII/FPI investors increased from 181 to 201 in Dec 2024 qtr.

Suven Pharmaceuticals Ltd.

24 Mar 2025

1151.00

3.68%

[Initiation] A play on the ADC growth segment

Buy: Suven Pharmaceuticals Ltd.

BOB Capital Markets Ltd.

ADC is an evolving second line of treatment in oncology. The company expects market size to grow to US$ 50bn by FY33 from US$ 5bn in FY22

Number of FII/FPI investors increased from 181 to 201 in Dec 2024 qtr.

Suven Pharmaceuticals Ltd.

03 Mar 2025

1151.00

3.68%

Indian pharma's capability, regulatory compliance help to tap global CDMO space'

Business Line

The progress India has made in terms of building the capabilities and number of scientists work in its favour.Also, India has a much better regulatory record than how it was perceived about 7 and 8 years ago': Suven Pharma's Executive Chairman Vivek Sharma

Suven Pharmaceuticals Ltd.'s price crossed above 50Day SMA today

Suven Pharmaceuticals Ltd.

20 Feb 2025

1151.00

3.68%

Suven Pharma soars 14% on heavy volumes; surges 43% from January low

Business Standard

Suven Pharma is set to benefit from high-growth cutting-edge CDMO segments and its proven track record to drive traditional business.

ICICI Securities Limited upgraded Suven Pharmaceuticals Ltd. to Buy with a price target of 1400.0 on 25 Mar, 2025.

Suven Pharmaceuticals Ltd.

20 Feb 2025

1151.00

3.68%

Macquarie initiates outperform rating on 4 Indian pharma stocks, sees 19-35% upside. Here's why

livemint

Indian pharma stocks: Macquarie favours Indian CDMOs, notably Divi's Labs and Suven Pharma, highlighting their superior scale and customer relationships. The Indian CRDMO market is projected to grow from US$7 billion to US$14 billion by 2028, driven by increased pharmaceutical outsourcing.

Suven Pharmaceuticals Ltd.'s price crossed above 50Day SMA today

Macquarie bullish on Suven Pharma, Divi's Labs, Bluejet and Syngene

Economic Times | 20 Feb 2025

Suven Pharmaceuticals Ltd.

13 Feb 2025

1151.00

3.68%

Suven Pharma shares zooms 12% on strong Q3 nos; PAT up 78%, rev 39%

Business Standard

Suven Pharma reported a 78 per cent rise in consolidated net profit during the third quarter to Rs 83.29 crore, as compared to Rs 46.75 crore in Q3FY24

ICICI Securities Limited upgraded Suven Pharmaceuticals Ltd. to Buy with a price target of 1400.0 on 25 Mar, 2025.

Suven Pharmaceuticals Ltd.

12 Feb 2025

1151.00

3.68%

Suven Pharmaceuticals Results Earnings Call for Q3FY25

Conference Call with Suven Pharmaceuticals Management and Analysts on Q3FY25 Performance and Outlook. Listen to the full earnings transcript.

Suven Pharmaceuticals Ltd.

27 Jan 2025

1151.00

3.68%

Suven Pharma looks for 6x increase in revenue by FY35

Business Today

Looking to the future, Suven's Horizon 2 initiative which includes plans to incorporate capabilities in flow chemistry, messenger ribonucleic acid (mRNA), and peptides by fiscal year 2030 is expected to enhance the company's position in advanced drug modalities.